A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Antimicrobial Efficacy of Topically Once or Twice Daily Applied Bisphosphocin® Nu-3 Gel At 5% and 10% Concentrations to Infected Diabetic Foot Ulcers (iDFU)
Latest Information Update: 10 Mar 2025
At a glance
- Drugs Nu 3 (Primary)
- Indications Diabetic foot ulcer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Lakewood Amedex
Most Recent Events
- 06 Mar 2025 Planned End Date changed from 1 Aug 2025 to 1 Aug 2026.
- 06 Mar 2025 Planned primary completion date changed from 1 Jun 2025 to 1 Jun 2026.
- 06 Mar 2025 Planned initiation date changed from 1 Dec 2024 to 1 Dec 2025.